Posts
Amended 2014-04-18: see bottom of this post!
I'm sure several readers remember a long series of posts across 2011-12, connected to a series of internal troubles in the management of the American Journal of Bioethics. One of the roots of all that mess was a controversy that eventually led to the resignation of Hilde Lindemann from the AJOB editorial board in protests of its managerial operations, followed by other weighty ones later by, e.g. Udo Schuklenk and John Lantos. Eventually, after much external pressure, following a less than elegantly handled stepping over to private business by then editor-in-chief, Glenn McGee (later to become CEO of the now defunct stem cell banking, cosmetics and therapeutic business RNL Europe), the drop-out of the AJOB operation of both him and his wife Summer Johnson McGee, who had initially been appointed to advance to co-editor with the new EiC appointed to succeed McGee.
The last post with any substance out of this mess was this one, and the entire series is found here.
The affair leading to the resignation of Lindemann connected to a critical scrutiny, and eventual letter to the FDA, signed by a large number of bioethicists, regarding some unresearched, non-evidence based, experimental off-label prenatal drug treatment at the Mount Sinai hospital with regard to congenital adrenal hyperplasia. This led to a long series of complicated controversies involving AJOB, later leading up to the developments summarised above, and one of those concerned the possible conflict of interests of several centrally placed AJOB managerial figures. Among those involved was Robert “Skip” Nelson, now editor-in-chief of the AJOB Empirical Bioethics journal, at the time ethicist linked to the FDA (he still is, as a matter of fact), who sent a letter to the Office for Human Research Protections on the Prenatal Dex case, as it came to be known, clearing the accused doctor of having broken any FDA regulations. Now it is reported that, apparently, Nelson at the same time had close and live ties, to AJOB and the people in the management who were deeply involved in one side of the controversy. That is, it is argued in a recent post by Alice Dreger and Ellen K Feder (who belong clearly to the other side, it must be added), one of the prime expert sources had hidden loyalties and dependencies that remained undisclosed and is now holding a gallant EiC title in the AJOB family of journals.
The whole story and argument is told much better than I ever could by Alice Dreger and Ellen K. Feder themselves at the superb Canadian Impact Ethics blog.
Amendment:
Skip Nelson contacted me personally after posting the first version of this report, and made clear that he finds nothing new in what is described by Dreger and Feder, that no payments to him from AJOB have ever been involved in his service as EiC, that he performs this job as part of his FDA assignment, and that what he claimed in his letter to the OHRP regarding Prenatal Dex remains true (Dreger's and Feder's view on that is set out here). Nelson also told me that he has no plan to respond publicly to Dreger and Feder. This post has been amended in the light of that in a few places above.
Showing posts with label Summer Johnson McGee. Show all posts
Showing posts with label Summer Johnson McGee. Show all posts
Thursday, 17 April 2014
Sunday, 16 September 2012
Further on what's Cookin' at AJOB and Bioethics.net
I have now received conformation and independent corroboration of the rumours and signs I reported about before, which due to a number of factors I was unsure how to assess. Summer Johnson McGee has indeed stepped out of the management of the American Journal of Bioethics, and also announced that she are cutting her ties to Bioethics.net. The actual letter, or email, of resignation has now been forwarded to me and is here shown in its entirety:
From: Summer <summer.mcgee@me.com>
Subject: Leaving AJOB
Date: 10 September 2012 2:31:21 PM CDT
Cc: "pwolpe@emory.edu Wolpe" <pwolpe@emory.edu>, "Robert \"Skip\" Nelson" <robert.nelson@fda.hhs.gov>, David Magnus <dmagnus@stanford.edu>
Friends of The American Journal of Bioethics and bioethics.net,I want to share with all of you that Friday, September 14, 2012 will be my last day at The American Journal of Bioethics and bioethics.net. In mid-August, I had detailed conversations with both David Magnus and the publisher about my desire to leave AJOB. I have elected also that bioethics.net, the blog, the weekly newsletter, and all of its social networking sites (Facebook, Twitter, LinkedIn) will no longer be owned and operated by me nor will the editorial office reside with me any longer. I have so enjoyed working with you as peers, and I owe you a succinct explanation for my departure. I firmly believe that we are right to be proud of the Journal's last twelve years, the first era of The American Journal of Bioethics. AJOB accomplished things that no one in bioethics or publishing thought possible, least of all its editors and staff. Until a few months ago, I often said that the work I did for AJOB felt impactful and rewarding, even important. AJOB no longer feels that way to me. Whether it is me, the field, or the journal that has changed, I know that I no longer want to lead our field's most cited journal.So, with thanks to those who have asked me not to depart, I feel I must leave the Journal, a decision made much easier because I know it is in the competent hands of David Magnus and the editorial staff he and I hired in the last few months. It has been a privilege to spend the last four years working with the journal’s editorial board, authors, peer reviewers, and readers. My departure from our journal is of course very emotional for me. AJOB has been my labor of love for a very long time. I thank each of you who contributed to that experience for me personally and professionally; your faith in the journal and in me has been unwavering and unforgettable.I wish The American Journal of Bioethics, its current editors, editorial board, and readers the best of luck in its next era. I bid you a fond, bittersweet, farewell.Cordially,Summer Johnson McGee, PhD
The bulk of the text is what is (or was) actually quoted in William Heisel's mysteriously shut down post at Reporting on health (of which you can read a web cached version here), which makes that shut down even more strange.
In any case, the text does not really throw any light on the specifics that has led to Summer's decision. Heisel, as I mentioned in my former post, has a vaguely hinted guess. And in a blog post at Psychology Today, bioethics researcher Alice Dreger offers further possible reasons for Johnson McGee to abandon ship. These, as it were, are further alleged conflict of interest cases that may have been severely manhandled by the old AJOB management, but which are not explicitly connected to the scandal around possibly pharma corrupted pain medication research, that I told about in the former posting, and more extensively in another one before. That is, there may be yet another complex of COI problems at AJOB to which Johnson McGee (and her husband and former editor in chief, Glenn McGee) might have been connected. In this case, the connection is to clinical experiments involving drugs and prenatal diagnosis on fetuses and children with hereditary abnormalities in the sex-hormone production, which Dreger and colleagues critically assess in a very recent article. In fact, this potential problem for AJOB is connected also to members of its editorial and conflict of interest boards, as well as the editor in chief of its sibling journal AJOB Primary Research, Robert Nelson.
In any case, Dreger in her post describes in exact terms what that is about, and reports that she and a colleague have just written the new AJOB management to look at the matter with fresh eyes in light of what has recently come to pass. The ball is now in the hands of suddenly sole editor in chief, David Magnus.
As for my own worries around the integrity of AJOB, having to do with the not very sound financial ties between the former editor in chief and Bioethics.net, things are still unclear. Nothing in Johnson McGee's letter makes any more clear how the relationship between the new AJOB management, AJOB itself and Bioethics.net now looks like. Do any of the editors of AJOB have financial interests in Bioethics.net that, together with the role of Bioethics.net in the AJOB operation, provide incentives for making editorial decisions based on other grounds that those that should guide a scientific editor? This remains to be seen.
In any case, the text does not really throw any light on the specifics that has led to Summer's decision. Heisel, as I mentioned in my former post, has a vaguely hinted guess. And in a blog post at Psychology Today, bioethics researcher Alice Dreger offers further possible reasons for Johnson McGee to abandon ship. These, as it were, are further alleged conflict of interest cases that may have been severely manhandled by the old AJOB management, but which are not explicitly connected to the scandal around possibly pharma corrupted pain medication research, that I told about in the former posting, and more extensively in another one before. That is, there may be yet another complex of COI problems at AJOB to which Johnson McGee (and her husband and former editor in chief, Glenn McGee) might have been connected. In this case, the connection is to clinical experiments involving drugs and prenatal diagnosis on fetuses and children with hereditary abnormalities in the sex-hormone production, which Dreger and colleagues critically assess in a very recent article. In fact, this potential problem for AJOB is connected also to members of its editorial and conflict of interest boards, as well as the editor in chief of its sibling journal AJOB Primary Research, Robert Nelson.
In any case, Dreger in her post describes in exact terms what that is about, and reports that she and a colleague have just written the new AJOB management to look at the matter with fresh eyes in light of what has recently come to pass. The ball is now in the hands of suddenly sole editor in chief, David Magnus.
As for my own worries around the integrity of AJOB, having to do with the not very sound financial ties between the former editor in chief and Bioethics.net, things are still unclear. Nothing in Johnson McGee's letter makes any more clear how the relationship between the new AJOB management, AJOB itself and Bioethics.net now looks like. Do any of the editors of AJOB have financial interests in Bioethics.net that, together with the role of Bioethics.net in the AJOB operation, provide incentives for making editorial decisions based on other grounds that those that should guide a scientific editor? This remains to be seen.
Saturday, 15 September 2012
Something's Cookin' at AJOB and Bioethics.net (Now Updated)
Updates added after the original post can be found at the bottom marked by bold text.
Yep, yep - there is definitely something going on - less clear, however, what it is and less clear how it connects to the long string of recent events around the American Journal of Bioethics and the important work of restoring confidence in the journal's integrity.
First, emails have this week been swishing around the bioethics scholarly community, quoting an alleged letter from Summer Johnson McGee announcing her resignation as editor in chief of the American Journal of Bioethics, as well as stepping out of the connected website business Bioethics.net. In both instances effective from September 14.
Second, William Heisel posted about and commented on this news and how it was viewed by remaining editor in chief, David Magnus on his blog at Reporting on Health, where he also quoted the above mentioned letter. The spirit of the post was that, possibly, perhaps as an add-on to the former troubles, Johnson McGee's unfortunate apparent connection to a number of recently announced and rather grave conflict of interest declaration problems at AJOB linked to an ongoing federal investigation of research corruption with pharma money at the former academic home of both AJOB, Bioethics.net and Johnson McGee may have become too much to handle.
However.......
Heisel's post has now been blocked for access since a few days (the link above is to a web-cache of the original page), and Johnson McGee is still listed as editor in chief at the journal website, where the press release announcing her recent appointment is also still available. Nothing is announced at Bioethics.net, except that the information about Summer Johnson McGee's ownership of the website through a company called Bioethics Internet Group that I quoted in my latest post on this topic has now been taken out (and someone has seen to it that former versions of Bioethics.net pages are not being cached). No word either in the AJOB Facebook group.
On twitter, people are asking Heisel about what's going on with no response so far – his account is silent since September 11, when he posted info about an update to the mentioned blog post. I was in contact with him via email the day before yesterday, but he did only want to talk on the phone about this matter and since we are 9 hours apart timezone-wise, this has not yet been possible to arrange. Or he has decided it wise not to communicate on the matter at this point.
Given the past occurrences of lawsuit threats in response to blog posts or articles connecting to AJOB and the businesses of its (now former) editorial management (see my last post on AJOB for more on that), it's not without that one is getting a bit worried. At the same time, if it really is true that Summer Johnson McGee is stepping down in the way indicated by all the rumors and signs, doing it in a cloud of civil law action would hardly make the whole thing more graceful, so I cross my fingers for her sake as well as Heisel's.
Hopefully, not least for AJOB's sake, all of these question marks will be straightened out soon. But, let's play with the thought that the initial rumor is true – what would that imply for AJOB? This, to my mind, depends on two things. First, Johnson McGee's actual connection to the recent round of problems around conflict of interest declarations and the linked alleged pharma corrupted research on pain medication. If this alleged link is weak or non-existent, Johnson McGee stepping down would not seem to help restoring confidence in AJOB through that route. Second, the point that I raised in my latest post on this topic about the problem of having an editor in chief that is directly financially dependent on what pieces are published in AJOB, through how that affects Bioethics.net traffic and advertisement revenue. This aspect of AJOB integrity is not fixed by Johnson McGee stepping down, since it remains to be known how the ownership of Bioethics.net looks from September 15, and how Bioethics.net will be connected to the AJOB operation in the future. Transparency on these points is absolutely crucial for AJOB's reputation, and something should ideally be posted about this in the about section at Bioethics.net and/or the journal website at the publisher as soon as possible.
Update, September 15, 2012:
Just now, when checking for news, I noticed that Summer Johnson McGee's name is off the editor-in-chief listing for AJOB in the about section for the journal at Bioethics.net. However, she is still listed at the actual journal homepage of the publisher Taylor and Francis.
The ownership of Bioethics.net and its role in the AJOB operation is still undeclared. In fact, the about section for Bioethics.net only speaks about AJOB, as if that is equivalent to Bioethics.net.
I can also report that the original web-cache link to Heisel's blog post was killed by Google (possibly on the request by someone of the involved parties), and has now been replaced by another service.
Yep, yep - there is definitely something going on - less clear, however, what it is and less clear how it connects to the long string of recent events around the American Journal of Bioethics and the important work of restoring confidence in the journal's integrity.
First, emails have this week been swishing around the bioethics scholarly community, quoting an alleged letter from Summer Johnson McGee announcing her resignation as editor in chief of the American Journal of Bioethics, as well as stepping out of the connected website business Bioethics.net. In both instances effective from September 14.
Second, William Heisel posted about and commented on this news and how it was viewed by remaining editor in chief, David Magnus on his blog at Reporting on Health, where he also quoted the above mentioned letter. The spirit of the post was that, possibly, perhaps as an add-on to the former troubles, Johnson McGee's unfortunate apparent connection to a number of recently announced and rather grave conflict of interest declaration problems at AJOB linked to an ongoing federal investigation of research corruption with pharma money at the former academic home of both AJOB, Bioethics.net and Johnson McGee may have become too much to handle.
However.......
Heisel's post has now been blocked for access since a few days (the link above is to a web-cache of the original page), and Johnson McGee is still listed as editor in chief at the journal website, where the press release announcing her recent appointment is also still available. Nothing is announced at Bioethics.net, except that the information about Summer Johnson McGee's ownership of the website through a company called Bioethics Internet Group that I quoted in my latest post on this topic has now been taken out (and someone has seen to it that former versions of Bioethics.net pages are not being cached). No word either in the AJOB Facebook group.
On twitter, people are asking Heisel about what's going on with no response so far – his account is silent since September 11, when he posted info about an update to the mentioned blog post. I was in contact with him via email the day before yesterday, but he did only want to talk on the phone about this matter and since we are 9 hours apart timezone-wise, this has not yet been possible to arrange. Or he has decided it wise not to communicate on the matter at this point.
Given the past occurrences of lawsuit threats in response to blog posts or articles connecting to AJOB and the businesses of its (now former) editorial management (see my last post on AJOB for more on that), it's not without that one is getting a bit worried. At the same time, if it really is true that Summer Johnson McGee is stepping down in the way indicated by all the rumors and signs, doing it in a cloud of civil law action would hardly make the whole thing more graceful, so I cross my fingers for her sake as well as Heisel's.
Hopefully, not least for AJOB's sake, all of these question marks will be straightened out soon. But, let's play with the thought that the initial rumor is true – what would that imply for AJOB? This, to my mind, depends on two things. First, Johnson McGee's actual connection to the recent round of problems around conflict of interest declarations and the linked alleged pharma corrupted research on pain medication. If this alleged link is weak or non-existent, Johnson McGee stepping down would not seem to help restoring confidence in AJOB through that route. Second, the point that I raised in my latest post on this topic about the problem of having an editor in chief that is directly financially dependent on what pieces are published in AJOB, through how that affects Bioethics.net traffic and advertisement revenue. This aspect of AJOB integrity is not fixed by Johnson McGee stepping down, since it remains to be known how the ownership of Bioethics.net looks from September 15, and how Bioethics.net will be connected to the AJOB operation in the future. Transparency on these points is absolutely crucial for AJOB's reputation, and something should ideally be posted about this in the about section at Bioethics.net and/or the journal website at the publisher as soon as possible.
Update, September 15, 2012:
Just now, when checking for news, I noticed that Summer Johnson McGee's name is off the editor-in-chief listing for AJOB in the about section for the journal at Bioethics.net. However, she is still listed at the actual journal homepage of the publisher Taylor and Francis.
The ownership of Bioethics.net and its role in the AJOB operation is still undeclared. In fact, the about section for Bioethics.net only speaks about AJOB, as if that is equivalent to Bioethics.net.
I can also report that the original web-cache link to Heisel's blog post was killed by Google (possibly on the request by someone of the involved parties), and has now been replaced by another service.
Sunday, 19 August 2012
Lots to do at the American Journal of Bioethics
As readers of this blog know, I have informed about and commented quite a bit on various controversies and debates surrounding the American Journal of Bioethics – when it comes to standard ways of ranking academic journals, the by far most influential of those in the field of bioethics and medical ethics, as well as celebrated for its pioneer editorial design with main "target articles" and rapid responses, plus a parallel publication online at the Bioethics.net, a research, news and comment portal for bioethics. Notwithstanding these qualities, the recent events I have been reporting about have undoubtedly scarred AJOB as an institution and left the current management with a challenging task of restoring lost trust. A short reminder:
1. A high profile resignation from the editorial board by Hilde Lindemann due to doubts about the soundness of the journal's editorial and managerial policies (here, here, here).
2. An impossible conflict of interest situation within the editorial management of AJOB created when former editor in chief Glenn McGee resigned to take up a post as full-time consultant for the private stem cell banking company, CellTex, while his wife (a distinguished bioethicist ijn her own right, but under default legislation, of course, sharing the financial ties of her husband), Summer Johnson McGee took over the AJOB rudder (together with David Magnus). It didn't help the case that Glenn McGee's resignation process and move to CellTex was far from ideally managed (creating lots of completely unnecessary questions) or that the Cell Tex operation itself is highly questioned among bioethics researchers. My reports and comments are here, here, here, here, here, here. The affair resolved itself when Glenn McGee announced his resignation from the CellTex job (thereby severing the vested conflict of interest ties affecting Summer Johnson McGee), but had at that point already effected two heavy resignations from the editorial board by John Lantos (who provided a strongly worded explanation) and Udo Schüklenk, himself editor in chief of the journal Bioethics (the latter however, still listed as a board member at the AJOB website).
This last affair had a bit of a semi-relevant aftermath, when CellTex, the stem cell company to which Glenn McGgee had been signed on to provide ethics consultancy threatened University of Minnesota bioethicist Leigh Turner (as well as his university) with lawsuits, when he wrote a letter to the FDA, urging them to investigate CellTex. Almost simultaneously, Glenn McGee did a very similar thing to Carl Elliott, a bioethics professor at the same university as Turner, for his published criticism of McGee's involvement with CellTex, leading to a retraction by the publisher Slate. See here, and here. None of those events, of course, did any good for the stained reputation of AJOB and one would have wished the journal some peace and quiet to be able to set the ship back on a straight course. However, it does not seem to end there.
Earlier this year, it was revealed that a leading researcher of the Center for Practical Bioethics, Myra Christopher was to be included in a US Senate probe into suspected heavy duty corruption due to the sponsoring from pharmacological companies in the area of pain medication and care. Now, until not very long time ago, both the McGee's were attached to CPB and Christopher herself is a member of the AJOB editorial board. So far pretty circumstantial and not really a link. However, a very recent revelation is that AJOB, when publishing an article with Christopher as co-author, neglected to publish a meaty description of her conflicts of interests due to the pharma sponsorship of CPB, plus missed (possibly due to omissions by Christopher to follow the proscribed COI disclosure procedure) other similar COI's of her co-authors. More details are at William Heisel's Reporting on Health blog; here and here. In any case the link between the troubles at AJOB and the serious allegations against CPB and Christopher is through this development clearly more than circumstantial. AJOB has allowed the possibly corrupt situation at CPB to enter into its midst, and it did so when its editor in chief and one other editor was academically based at CPB, so that the journal was effectively run from there, and even more so its parallel online extension Bioethics.net.
Now, queried by Reporting on Health, David Magnus, one of the new editors in chief of AJOB described how steps are now taken to beef up the COI disclosure procedures of the journal. Together with the resolving of the conflict of interest situation, this bodes well for the journal's future, albeit the uphill that has to be climbed by Magnus and Johnson McGee and their co-workers on the editorial and managerial side of AJOB has not exactly become less steep. Being a fan of AJOB, it makes me happy to detect Magnus' resolve to clear up any remaining irregularities or integrity problems at AJOB, and thus take important steps to restore its reputation.
One of the things that continues to create suspicion and confusion is the relation and connection between AJOB and Bioethics.net. This, I assume what was explained Hilde Lindemann's doubts with regard to the ownership of AJOB, and the latest post at Reporting on Health displays confusion around where information about AJOB is to be had – at the T&F website of the journal or at Bioethics.net. It has, through the first of the controversies mentioned above, been made very clear that AJOB is owned and published by Taylor & Francis, which in turn are not involved in the ownership or operation of Bioethics.net. But, of course, there is a business deal of some sort between T&F and Bioethics.net, lest the latter would not be able to offer its members automatic access to all AJOB material or so vigorously promote AJOB (no doubt contributing to its popularity and impact). When I checked before, when controversy no. 2 above was going on, none of these things were made very clear at the Bioethics.net website. However, the information given has now clearly improved and the ownership of Bioethics.net as well as its business link to AJOB is now described in the Bioethics.net "about" section, thus:
In any case, another matter for Magnus, Johnson McGee and the editorial board – as well as responsible officers at Taylor & Francis, of course – to ponder as they all continue their efforts to restore AJOB to its former glory.
1. A high profile resignation from the editorial board by Hilde Lindemann due to doubts about the soundness of the journal's editorial and managerial policies (here, here, here).
2. An impossible conflict of interest situation within the editorial management of AJOB created when former editor in chief Glenn McGee resigned to take up a post as full-time consultant for the private stem cell banking company, CellTex, while his wife (a distinguished bioethicist ijn her own right, but under default legislation, of course, sharing the financial ties of her husband), Summer Johnson McGee took over the AJOB rudder (together with David Magnus). It didn't help the case that Glenn McGee's resignation process and move to CellTex was far from ideally managed (creating lots of completely unnecessary questions) or that the Cell Tex operation itself is highly questioned among bioethics researchers. My reports and comments are here, here, here, here, here, here. The affair resolved itself when Glenn McGee announced his resignation from the CellTex job (thereby severing the vested conflict of interest ties affecting Summer Johnson McGee), but had at that point already effected two heavy resignations from the editorial board by John Lantos (who provided a strongly worded explanation) and Udo Schüklenk, himself editor in chief of the journal Bioethics (the latter however, still listed as a board member at the AJOB website).
This last affair had a bit of a semi-relevant aftermath, when CellTex, the stem cell company to which Glenn McGgee had been signed on to provide ethics consultancy threatened University of Minnesota bioethicist Leigh Turner (as well as his university) with lawsuits, when he wrote a letter to the FDA, urging them to investigate CellTex. Almost simultaneously, Glenn McGee did a very similar thing to Carl Elliott, a bioethics professor at the same university as Turner, for his published criticism of McGee's involvement with CellTex, leading to a retraction by the publisher Slate. See here, and here. None of those events, of course, did any good for the stained reputation of AJOB and one would have wished the journal some peace and quiet to be able to set the ship back on a straight course. However, it does not seem to end there.
Earlier this year, it was revealed that a leading researcher of the Center for Practical Bioethics, Myra Christopher was to be included in a US Senate probe into suspected heavy duty corruption due to the sponsoring from pharmacological companies in the area of pain medication and care. Now, until not very long time ago, both the McGee's were attached to CPB and Christopher herself is a member of the AJOB editorial board. So far pretty circumstantial and not really a link. However, a very recent revelation is that AJOB, when publishing an article with Christopher as co-author, neglected to publish a meaty description of her conflicts of interests due to the pharma sponsorship of CPB, plus missed (possibly due to omissions by Christopher to follow the proscribed COI disclosure procedure) other similar COI's of her co-authors. More details are at William Heisel's Reporting on Health blog; here and here. In any case the link between the troubles at AJOB and the serious allegations against CPB and Christopher is through this development clearly more than circumstantial. AJOB has allowed the possibly corrupt situation at CPB to enter into its midst, and it did so when its editor in chief and one other editor was academically based at CPB, so that the journal was effectively run from there, and even more so its parallel online extension Bioethics.net.
Now, queried by Reporting on Health, David Magnus, one of the new editors in chief of AJOB described how steps are now taken to beef up the COI disclosure procedures of the journal. Together with the resolving of the conflict of interest situation, this bodes well for the journal's future, albeit the uphill that has to be climbed by Magnus and Johnson McGee and their co-workers on the editorial and managerial side of AJOB has not exactly become less steep. Being a fan of AJOB, it makes me happy to detect Magnus' resolve to clear up any remaining irregularities or integrity problems at AJOB, and thus take important steps to restore its reputation.
One of the things that continues to create suspicion and confusion is the relation and connection between AJOB and Bioethics.net. This, I assume what was explained Hilde Lindemann's doubts with regard to the ownership of AJOB, and the latest post at Reporting on Health displays confusion around where information about AJOB is to be had – at the T&F website of the journal or at Bioethics.net. It has, through the first of the controversies mentioned above, been made very clear that AJOB is owned and published by Taylor & Francis, which in turn are not involved in the ownership or operation of Bioethics.net. But, of course, there is a business deal of some sort between T&F and Bioethics.net, lest the latter would not be able to offer its members automatic access to all AJOB material or so vigorously promote AJOB (no doubt contributing to its popularity and impact). When I checked before, when controversy no. 2 above was going on, none of these things were made very clear at the Bioethics.net website. However, the information given has now clearly improved and the ownership of Bioethics.net as well as its business link to AJOB is now described in the Bioethics.net "about" section, thus:
Bioethics.net is owned and operated by Bioethics Internet Group. Bioethics Internet Group (BIG) is wholly owned by Summer Johnson McGee, Ph.D. Funding for bioethics.net is provided by paid banner advertisements appearing on the website and a stipend from Taylor and Francis, Inc.To me, this explains a lot why it "had" to be Summer Johnson McGee who took over the rudder when Glenn McGee resigned to take up the CellTex job. Although separate financial and organisational entities, only one of which with financial ties to the McGee's, Bioethics.net and AJOB are very much dependent on each other. Or AJOB is at least dependent on Bioethics.net to the extent that the latter does contribute to the success of the journal. Or perhaps the double involvement in Bioethics.net and AJOB helps to fund the no doubt unusually complicated editorial operation of the journal's ambitious design? In any case, it would seem very probable that Bioethics.net stands and falls as a business with the link to AJOB. So far, perhaps not much of a problem for AJOB from an integrity perspective. But it may need to be discussed to what extent it may be a problem that the editor in chief of AJOB has a direct financial interest in what is being published by AJOB (since that will affect the traffic of Bioethics.net and, through that, advertisement revenue of BIG, owned by Johnson McGee).
In any case, another matter for Magnus, Johnson McGee and the editorial board – as well as responsible officers at Taylor & Francis, of course – to ponder as they all continue their efforts to restore AJOB to its former glory.
Saturday, 25 February 2012
David Magnus Defends the New Managerial Solution for AJOB as Udo Schuklenk Resigns from the Editorial Board
At last, there is word directly from the bench of the accused in the recent controversy regarding the new managerial solution for the American Journal of Bioethics after the Glenn McGee resigned as editor in chief to join a rather dodgy private stem cell company [since Slate retracted the article linked to here, apparently following threats of lawsuits from McGee, this link is now broken. Thanks to Nature, the background on the murky business of CellTex is still around, however] as full-time adviser/lobbyist/expert. My former posts on this matter are here: 1, 2, 3, 4 and 5. Today, I learned that another heavy resignation from the board of editors following these events has occurred: Udo Schuklenk has announced that he steps down from this position, preferring to keep his exact reasons confidential with reference to being being part of the editorial management of a competing journal, Bioethics.
David Magnus, one of the two newly appointed editors in chief – the other being Summer Johnson McGee, whose appointment I have criticised – addresses the rather rich variety of critical reactions to the new AJOB order, as well as its background, in a post at AJOB's adjunct blog. Given the amount of criticism that I have been mounting, I think it is only fair to cross post what David writes in its entirety (my comments can be found below, after the post):
1. Yes, through Summer Johnson McGee's marriage to Glenn McGee, AJOB does have a clear-cut conflict of (vested) interest built into its editorial management, but that may very well be the case with other journals too!
This hardly needs comment, does it? Imagine a prosecutor arguing thus: I have clear evidence to prosecute person P for the crime C, but since there are possible other individuals that might have been possible to prosecute for other crimes, had I only had the evidence, prosecuting P for C is out of the question. Case closed.
2. AJOB will be beefing up its organisation for handling the actualisation of the COI of Summer Johnson McGee (and other COI's that may appear) in particular cases, so that it does not wholly depend on the subjective judgement of the person attached to the COI, or other people of the editorial management, alone, but another three people recruited from the editorial boards of all AJOB journals.
This seems like a necessary minimal step given 1, but is it sufficient? Well, in the end this comes down to trust, doesn't it? My position here is rather like the one voiced by John Lantos: In the face of a journal that prefers to house and attempt to "manage" a serious COI in the midst of its highest management when it is quite possible to avoid it in the first place, I do not feel a tingling buzz of increased confidence and trust, rather the other way around. I, as I suspect most of my colleagues do, ask myself the obvious question: why does David Magnus make this far from necessary choice that seriously threatens the credibility of the journal? Why, for instance, does he not start with a clean editorial slate and manage the practicalities of the transition by engaging both McGee and Johnson McGee in temporary advisory capacities to this effect – naturally, rewarded to the extent that their high qualifications and competence require? The point here is not that there may be answers to these questions and that the string of follow-up questions and subsequent answers may go on for a long time. The point is that, from the point of view of the best interest of the journal, there are obvious strategies to avoid having these questions being actualised in the first place. Not choosing these from the start undermines trust, and trust is what David Magnus above asks of all of us who care for the integrity of AJOB and the field of bioethics research. It doesn't add up, simple as that.
David Magnus, one of the two newly appointed editors in chief – the other being Summer Johnson McGee, whose appointment I have criticised – addresses the rather rich variety of critical reactions to the new AJOB order, as well as its background, in a post at AJOB's adjunct blog. Given the amount of criticism that I have been mounting, I think it is only fair to cross post what David writes in its entirety (my comments can be found below, after the post):
David Magnus Corrects the Record Regarding AJOB
Over the past couple of weeks, a great deal of drama has played out regarding changes at the American Journal of Bioethics. While we appreciate all of the support we have received from our Editorial Board and much of the leadership in the field, a number of misleading or false claims have been made about which I feel obligated to respond.
Going forward, Summer and I have a lot of exciting plans for AJOB. We plan on creating several committees (not just a COI committee) to explore ways of improving and expanding the journal and bioethics publishing generally. We also look forward to instating a business meeting for our Editorial Board at ASBH each year, a working meeting where we will update our board members on the state of AJOB, solicit their opinions, and hear reports from the committees we have created. These are but two ideas among many that we plan to institute. We have two new Associate Editors who have agreed to join us (we will send an announcement about this shortly). And we are excited about the opportunity to lead AJOB—the most cited journal in the field.
- It has been claimed that the Editorial offices of AJOB were relocated to Celltex. This is false. It is a matter of public record that the offices of the journal have been and continue to be based at 3030 Post Oak Blvd. #805 in Houston, Texas. These are not the offices of Celltex and Celltex housed no AJOB editorial office or AJOB activity on their premises.
- It has been claimed that Glenn McGee took the job at Celltex and planned to continue to serve as both EIC of AJOB while working at Celltex until bloggers and twitter revelations forced a hasty change in plans. In fact, when Glenn first decided that he was likely to move to the private sector, he decided it would be best to resign from AJOB. Transition plans began then—and this can be attested to by a number of leaders within the field of bioethics, since a number of them were aware of the transition plans.
- Most of the attacks fail to acknowledge that Glenn had already been working to transition out of his role at AJOB as soon as he accepted his new position. During the transition he had no role in the oversight or acceptance of manuscripts for the journal. Failure to acknowledge that he was in the process of transitioning out of AJOB and that conflict of interest provisions had been put in place is a misleading rendition of events.
- Charges of nepotism have been raised against the appointment of Summer Johnson McGee as the co-EIC of AJOB. This charge is false. It was my idea (not Glenn’s) for Summer to be proposed as co-EIC. It was up to Taylor and Francis (not Glenn and not me) to make the final decision to sign her to a long-term contract as co-EIC. This is one of the more offensive charges, since it fails to acknowledge the reality that Summer is a scholar in her own right and that she is in fact the backbone of the journal. Anyone familiar with the workings of the journal knows that Summer has taken on more and more responsibility for the journal over the past several years—unfortunately while getting little recognition for her contributions.
- There has also been a charge that Summer is too conflicted to serve as co-EIC or that her COI cannot be managed or mitigated. This issue has already been addressed, but to reiterate: conflicts of interest are ubiquitous among journal editors. What is unusual in this case is that one of the sources of spousal COI is actually known. In contrast, most of us know very little about what, if any, COI issues exist regarding spouses or other family members of most bioethics journals (for the record, my wife is a public librarian). As we have already stated, Summer will have to recuse herself from any possible COI, including those that may arise out of the fact that her husband works for a stem cell company. I do not believe that this will be hard and knowing the range of manuscripts that we typically review, it will be a minority of submissions. I will personally review all manuscript submissions (as will Summer) and no editor will be involved in manuscripts for which they have a COI. Since we have two co-EIC’s and two new Associate Editors, we believe that it should be relatively easy to divide any labor. To improve our management of COI issues and to update our now 10 year old COI policy, we are shortly going to be looking for volunteers among the three Editorial Boards to create a standing COI committee and charge them with helping to create guidelines and processes for better managing COI’s. We have actually been successfully managing conflicts of interest among ourselves for a long time (for example, an article was recently accepted that was written by one of my faculty) and there is no reason to believe that recusing Summer from reviewing the manuscripts where a COI exists can not be accomplished.
David Magnus, PhDNow, of these sorts of criticism, I have wielded only one, the fifth and last one, although I did point out in my initial post that the handling of the publication of the transition, its procedural steps and its background has been far from as open, professional and clear-cut as one would have expected from the leading journal of a flourishing field of research. Apart from not appreciating the impact on trust of the many serious mistakes that has been made in this process (by the former and/or the new management, by Taylor & Francis, and so on), David, I think, addresses several of the points of criticism fairly well. However, I do think that his take on the fifth still leaves much to ask for. What he says in so many words is this:
1. Yes, through Summer Johnson McGee's marriage to Glenn McGee, AJOB does have a clear-cut conflict of (vested) interest built into its editorial management, but that may very well be the case with other journals too!
This hardly needs comment, does it? Imagine a prosecutor arguing thus: I have clear evidence to prosecute person P for the crime C, but since there are possible other individuals that might have been possible to prosecute for other crimes, had I only had the evidence, prosecuting P for C is out of the question. Case closed.
2. AJOB will be beefing up its organisation for handling the actualisation of the COI of Summer Johnson McGee (and other COI's that may appear) in particular cases, so that it does not wholly depend on the subjective judgement of the person attached to the COI, or other people of the editorial management, alone, but another three people recruited from the editorial boards of all AJOB journals.
This seems like a necessary minimal step given 1, but is it sufficient? Well, in the end this comes down to trust, doesn't it? My position here is rather like the one voiced by John Lantos: In the face of a journal that prefers to house and attempt to "manage" a serious COI in the midst of its highest management when it is quite possible to avoid it in the first place, I do not feel a tingling buzz of increased confidence and trust, rather the other way around. I, as I suspect most of my colleagues do, ask myself the obvious question: why does David Magnus make this far from necessary choice that seriously threatens the credibility of the journal? Why, for instance, does he not start with a clean editorial slate and manage the practicalities of the transition by engaging both McGee and Johnson McGee in temporary advisory capacities to this effect – naturally, rewarded to the extent that their high qualifications and competence require? The point here is not that there may be answers to these questions and that the string of follow-up questions and subsequent answers may go on for a long time. The point is that, from the point of view of the best interest of the journal, there are obvious strategies to avoid having these questions being actualised in the first place. Not choosing these from the start undermines trust, and trust is what David Magnus above asks of all of us who care for the integrity of AJOB and the field of bioethics research. It doesn't add up, simple as that.
Thursday, 23 February 2012
Mike King on My Take on the Sexism Accusation re. Criticism of New AJOB Management.
Mike King of the Bioethics Centre at the University of Otago, New Zealand, has provided an interesting comment to my latest post on the issue of a severe conflicts of interest within the new management of the American Journal of Biotehics.
Mike points out that, apparently, some of the leaning on AJOB and the McGee's around the net may have been read as a slanderous rant about Summer Johnson McGee not being qualified for the job of editor in chief, but getting it only because of her marriage to Glenn McGee, the resigning editor in chief, or – alternatively – that Johnson McGee, as a woman, would be unable to think for herself in relation to her husband.
I agree wholeheartedly with Mike King that if this was all there was to the criticism against AJOB, this criticism would indeed be nothing more than a dirty piece of sexist garbage. However, arguments of the sort alluded to have certainly not been what I have been set forth as the basis of my criticism (see my former posts, starting with last one linked to above). Neither is it to be found in the critical messages of Howard Brody or John Lantos. And, frankly, I cannot see how anyone could read that into either of our critical contributions on this matter.
So, just to be crystal. crystal clear: my claim is based on the fact that the link of marriage between the old and the new editor in chief preserves the vested conflicts of interest created by the former signing on as full time consultant for a dodgy, private stem cell therapy company. This since marriage by default makes the financial interests of spouse intertwined.
That's all there is to it.
Mike points out that, apparently, some of the leaning on AJOB and the McGee's around the net may have been read as a slanderous rant about Summer Johnson McGee not being qualified for the job of editor in chief, but getting it only because of her marriage to Glenn McGee, the resigning editor in chief, or – alternatively – that Johnson McGee, as a woman, would be unable to think for herself in relation to her husband.
I agree wholeheartedly with Mike King that if this was all there was to the criticism against AJOB, this criticism would indeed be nothing more than a dirty piece of sexist garbage. However, arguments of the sort alluded to have certainly not been what I have been set forth as the basis of my criticism (see my former posts, starting with last one linked to above). Neither is it to be found in the critical messages of Howard Brody or John Lantos. And, frankly, I cannot see how anyone could read that into either of our critical contributions on this matter.
So, just to be crystal. crystal clear: my claim is based on the fact that the link of marriage between the old and the new editor in chief preserves the vested conflicts of interest created by the former signing on as full time consultant for a dodgy, private stem cell therapy company. This since marriage by default makes the financial interests of spouse intertwined.
That's all there is to it.
Wednesday, 22 February 2012
The Conflict of Interest Claim Towards New AJOB Editorial Arrangement is not Sexist
The controversy surrounding the new editorial arrangement for the American Journal of Bioethics after Glenn McGee decided to step down in order to work full time as consultant for stem cell company CellTex (covered in former posts here, here and here) continues, now in the landscape of big science, in this news article in Nature.
In the article, new editor in chief, Summer Johnson McGee defends the decision of publisher Taylor & Francis to appoint her editor in chief against the criticism that this cements rather than resolves the conflict of interest created by Glenn McGee's move to industry:
Now, the firtst line of defense here has already been addressed by the critics, in particular by John Lantos, who resigned from the AJOB editorial board over this matter. And I happen to agree with John about how much of a wife-of-Ceasar-principle has to be applied in the case of defending the credibility of bioethics journals. Simply put: one of the well-known logics of conflicts of interests is that they tend to make you bad at spotting where the conflict is actualised in particular cases. Thus, the report c-o-i based on subjective perception principle is not by itself good enough. A broader margin of safety against suspicion is required to uphold the credibility of a leading ethics journal.
More interesting is Johnson McGee's second line of defense. The claim of "baselessness" is, of course a complete misnomer and question-begger. It is a fact that she and Glenn McGee are married and that, in virtue of that arrangement, vested interests of Glenn McGee are by default also such interests of Summer Johnson McGee. Therefore, I have argued, the conflict of interest is not resolved but rather sustained by switching from one to the other in the leading editorial management role of AJOB.
Now, this way of arguing is, Johnson McGee seems to hold, sexist. Well, Summer, allow me to retort that it is in fact this very line of defense of yours that is a case of sexism. The argument based on default economic relations between spouse holds regardless of the sex or gender of the people involved in this relationship. That is, my argument would have stuck just as much had the roles between you and Glenn been reversed (you being the one leaving the e-i-c position for industry, and Glenn taking up your managerial torch). What you seem to claim is that you should be let off the hook because you happen to be a woman. That, if anything, is a sexist line of argument.
If this is all there to say in defense of the new AJOB editorial arrangements, I would say that the state of things in the management of this journal appear to be even worse than what they appeared to be before. For I cannot convince myself that even Johnson McGee herself seriously believes in what she tries to sell through Nature. This, I would say is not the voice of conviction, but of desperation.
In the article, new editor in chief, Summer Johnson McGee defends the decision of publisher Taylor & Francis to appoint her editor in chief against the criticism that this cements rather than resolves the conflict of interest created by Glenn McGee's move to industry:
Responding to questions from Nature, Summer Johnson McGee says that the journal has a conflict-of-interest policy that requires editors to withdraw from reviewing a manuscript if they perceive a conflict. She calls allegations that her appointment results from her relationship with her husband “baseless and sexist”.
Now, the firtst line of defense here has already been addressed by the critics, in particular by John Lantos, who resigned from the AJOB editorial board over this matter. And I happen to agree with John about how much of a wife-of-Ceasar-principle has to be applied in the case of defending the credibility of bioethics journals. Simply put: one of the well-known logics of conflicts of interests is that they tend to make you bad at spotting where the conflict is actualised in particular cases. Thus, the report c-o-i based on subjective perception principle is not by itself good enough. A broader margin of safety against suspicion is required to uphold the credibility of a leading ethics journal.
More interesting is Johnson McGee's second line of defense. The claim of "baselessness" is, of course a complete misnomer and question-begger. It is a fact that she and Glenn McGee are married and that, in virtue of that arrangement, vested interests of Glenn McGee are by default also such interests of Summer Johnson McGee. Therefore, I have argued, the conflict of interest is not resolved but rather sustained by switching from one to the other in the leading editorial management role of AJOB.
Now, this way of arguing is, Johnson McGee seems to hold, sexist. Well, Summer, allow me to retort that it is in fact this very line of defense of yours that is a case of sexism. The argument based on default economic relations between spouse holds regardless of the sex or gender of the people involved in this relationship. That is, my argument would have stuck just as much had the roles between you and Glenn been reversed (you being the one leaving the e-i-c position for industry, and Glenn taking up your managerial torch). What you seem to claim is that you should be let off the hook because you happen to be a woman. That, if anything, is a sexist line of argument.
If this is all there to say in defense of the new AJOB editorial arrangements, I would say that the state of things in the management of this journal appear to be even worse than what they appeared to be before. For I cannot convince myself that even Johnson McGee herself seriously believes in what she tries to sell through Nature. This, I would say is not the voice of conviction, but of desperation.
Friday, 17 February 2012
Press release from Taylor & Francis on the New AJOB Management
Relating to my two posts yesterday on the controversy surrounding this (here and here): Today, via Twitter and Facebook, a press release from the publisher of the American Journal of Bioethics, scientific publishing giant Taylor & Francis, on the journal's new managerial arrangements has been distributed. Anyone can get it from here.
In short, T & F simply announces the new arrangement: Summer Johnson McGee and David Magnus as the new editor in chief team and states that Glenn McGee is "retiring", while advising the transfer to the new arrangements over a 2 months period (which is perfectly in order). Unsurprisingly, there is no comment whatsoever of the criticism that the new arrangement has attracted. There is, however, an attempt at an explanation of why Summer Johnson McGee is to be EiC in spite of her sharing the conflict of interest that explains Glenn McGee's resignation (due to their marriage): David Magnus demanded this arrangement for accepting himself stepping in as EiC. This explanation was commented on by John Lantos in yesterday's post. In short: if this is indeed the reason for the new arrangements it is, in extension, a worrying sign of poor judgement and undue focus on practicalities over integrity of both Magnus and Taylor & Francis.
Now, I can see the reason for wanting Summer Johnson McGee to go on with AJOB: she has been working with the journal (and it's sibling website and blog) in an executive capacity for a long time and probably know all the ropes better than most others. However, such practical reasons weigh lightly when balanced against the credibility, integrity and reputation of AJOB and it's spin-off journals. Not to belittle the competence and experience of either Glenn McGee or Summer Johnson McGee or David Magnus (should his condition for accepting to be EiC be as firm as it sounds), but these are things that can be passed on to other people where no embarrassing conflict of interest ties staining the reputation of AJOB will exist.
So I land once again in the conlusion I announced yesterday: AJOB is a fantastic achievement. But in light of the carreer choice made by Glenn McGee, to remain fantatstic it needs to completely severe all ties (except, of course, the recognition as founder and former management) - direct as well as indirect - to him – which, as things stand, includes also Summer Johnson McGee. As indicated by John Lantos, it is both surprising and rather disturbing that this is not obvious to David Magnus and the representatives of Taylor & Francis.
In short, T & F simply announces the new arrangement: Summer Johnson McGee and David Magnus as the new editor in chief team and states that Glenn McGee is "retiring", while advising the transfer to the new arrangements over a 2 months period (which is perfectly in order). Unsurprisingly, there is no comment whatsoever of the criticism that the new arrangement has attracted. There is, however, an attempt at an explanation of why Summer Johnson McGee is to be EiC in spite of her sharing the conflict of interest that explains Glenn McGee's resignation (due to their marriage): David Magnus demanded this arrangement for accepting himself stepping in as EiC. This explanation was commented on by John Lantos in yesterday's post. In short: if this is indeed the reason for the new arrangements it is, in extension, a worrying sign of poor judgement and undue focus on practicalities over integrity of both Magnus and Taylor & Francis.
Now, I can see the reason for wanting Summer Johnson McGee to go on with AJOB: she has been working with the journal (and it's sibling website and blog) in an executive capacity for a long time and probably know all the ropes better than most others. However, such practical reasons weigh lightly when balanced against the credibility, integrity and reputation of AJOB and it's spin-off journals. Not to belittle the competence and experience of either Glenn McGee or Summer Johnson McGee or David Magnus (should his condition for accepting to be EiC be as firm as it sounds), but these are things that can be passed on to other people where no embarrassing conflict of interest ties staining the reputation of AJOB will exist.
So I land once again in the conlusion I announced yesterday: AJOB is a fantastic achievement. But in light of the carreer choice made by Glenn McGee, to remain fantatstic it needs to completely severe all ties (except, of course, the recognition as founder and former management) - direct as well as indirect - to him – which, as things stand, includes also Summer Johnson McGee. As indicated by John Lantos, it is both surprising and rather disturbing that this is not obvious to David Magnus and the representatives of Taylor & Francis.
Thursday, 16 February 2012
John Lantos resigns from the AJOB editorial board
As a direct result of the affair with regard to the American Journal of Bioethics that I discussed in my former post, John Lantos, Director of the Children's Mercy Bioethics Center and Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine, as well as Fellow of Clinical Medical Ethics at the University of Chicago, to which he belonged for over 20 years, just announced his resignation from the editorial board of AJOB via a post in the closed Facebook group Bioethics International. I've contacted John and he has given me permission to quote this post here, which I will do without further comment:
Confidence Lost: The McGee's, Celltex and the American Journal of Bioethics
The past week or so, a new controversy related to the vastly successful journal The American Journal of Bioethics and its management has been a growing buzz in my field of research speciality. I have reported before about such a controversy (here, here and here), which in that case rather quickly deteriorated into a storm of more and more personal accusations between what at the time looked to me as a bunch of rather overinflated egos, of less and less interest from a bioethics point of view. There was also a very strange former questioning of AJOB's fine impact factor, which I will not even link to here, since it was obviously based on lies about it being based on high degree of internal citations. In fact, AJOB has less degrees of internal citations than most other ethics journals tracked by Thomson Reuter. The journal AJOB is a success, and it is a real success especially in terms of making bioethics publication have a real impact on medicine and medical science – hence the fine citation record, which anyone can use their university's Web of Science subscription to check. 'Nuff said on that.
This latest scandal, however, seems to me to be more of a real deal. This since there are a number of principal matters of publication ethics and bioethics implied, rather than just controversy over singular editorial policy decisions and insubstantiated slander. The matters are:
1. Glenn McGee's handling of his shift from editor in chief of AJOB to President of Ethics and Strategic Initiatives of the private stem cell business CellTex. The verdict has to be: not very nicely done at all. See: Leigh Turner's blog for more.
2. The attempt to resolve the obvious conflict of interest created by that shift by appointing McGee's wife, Summer Johnson McGee as the new EIC and for Glenn McGee to keep some managerial (rather than just ceremonial in terms of founder, full stop) ties to AJOB. See the previous link and this one for more. The vested interests of Glenn McGee in terms of his financial ties to CellTex cannot, in my view, be separated from those of Summer Johnson McGee for the very reason that they are married and thereby under default arrangement share private economic interests and resources.
3. The issue of the ethics of a bioethics scholar to assist a firm that offers non-FDA approved stem cell therapies in a manner that very much resembles the activities of the Burzynski clinic that I have been posting about. Read more about this here.
4. The implied result of having Glenn McGee more or less indirectly in a position of power in relation to an FDA-connected editor of a journal in the AJOB family, where publications may influence whether or not CellTex products will eventually receive FDA clearance. (see previous links).
I personally like AJOB and its special editorial idea very much and I also have the highest regard for its contribution to the positioning of bioethics as a research speciality, but the combination of the above four matters taken together cannot but leave an ugly stain on its record of credibility. By themselves, they also each stain the credibility of both Glenn McGee and Summer Johnson McGee as bioethics scholars. By implication, this taints also other people involved in the managerial and editorial operation around AJOB. But the root of all this is the ruined credibility of Glenn McGee as bioethics scholar.
Simply put, Glenn: how can I from this day know what master you speak for when you make decisions, assessments, arguments, and so on? As a bioethics colleague: why isn't your first action re. CellTex the obvious one of refusing to be affiliated with it before they either close down their questionable operations or obtain proper approval for their activities?? None of the answers to the latter question that I can imagine inspire confidence, I'm afraid. In light of this, how could you ever imagine that the moves made regarding the management of AJOB would get the journal off the hook in terms of conflicts of interests and reduced credibility. AJOB is your child, I can see that, and I can also see that you care very much for this child of yours to do well in your absense. However, the path entered by the decisions made in recent times is not promoting that end, quite the opposite.
This latest scandal, however, seems to me to be more of a real deal. This since there are a number of principal matters of publication ethics and bioethics implied, rather than just controversy over singular editorial policy decisions and insubstantiated slander. The matters are:
1. Glenn McGee's handling of his shift from editor in chief of AJOB to President of Ethics and Strategic Initiatives of the private stem cell business CellTex. The verdict has to be: not very nicely done at all. See: Leigh Turner's blog for more.
2. The attempt to resolve the obvious conflict of interest created by that shift by appointing McGee's wife, Summer Johnson McGee as the new EIC and for Glenn McGee to keep some managerial (rather than just ceremonial in terms of founder, full stop) ties to AJOB. See the previous link and this one for more. The vested interests of Glenn McGee in terms of his financial ties to CellTex cannot, in my view, be separated from those of Summer Johnson McGee for the very reason that they are married and thereby under default arrangement share private economic interests and resources.
3. The issue of the ethics of a bioethics scholar to assist a firm that offers non-FDA approved stem cell therapies in a manner that very much resembles the activities of the Burzynski clinic that I have been posting about. Read more about this here.
4. The implied result of having Glenn McGee more or less indirectly in a position of power in relation to an FDA-connected editor of a journal in the AJOB family, where publications may influence whether or not CellTex products will eventually receive FDA clearance. (see previous links).
I personally like AJOB and its special editorial idea very much and I also have the highest regard for its contribution to the positioning of bioethics as a research speciality, but the combination of the above four matters taken together cannot but leave an ugly stain on its record of credibility. By themselves, they also each stain the credibility of both Glenn McGee and Summer Johnson McGee as bioethics scholars. By implication, this taints also other people involved in the managerial and editorial operation around AJOB. But the root of all this is the ruined credibility of Glenn McGee as bioethics scholar.
Simply put, Glenn: how can I from this day know what master you speak for when you make decisions, assessments, arguments, and so on? As a bioethics colleague: why isn't your first action re. CellTex the obvious one of refusing to be affiliated with it before they either close down their questionable operations or obtain proper approval for their activities?? None of the answers to the latter question that I can imagine inspire confidence, I'm afraid. In light of this, how could you ever imagine that the moves made regarding the management of AJOB would get the journal off the hook in terms of conflicts of interests and reduced credibility. AJOB is your child, I can see that, and I can also see that you care very much for this child of yours to do well in your absense. However, the path entered by the decisions made in recent times is not promoting that end, quite the opposite.
Subscribe to:
Posts (Atom)